WO2019174003A1 - 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用 - Google Patents

植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用 Download PDF

Info

Publication number
WO2019174003A1
WO2019174003A1 PCT/CN2018/079154 CN2018079154W WO2019174003A1 WO 2019174003 A1 WO2019174003 A1 WO 2019174003A1 CN 2018079154 W CN2018079154 W CN 2018079154W WO 2019174003 A1 WO2019174003 A1 WO 2019174003A1
Authority
WO
WIPO (PCT)
Prior art keywords
dehp
lactobacillus plantarum
metabolites
plasticizer
fermented food
Prior art date
Application number
PCT/CN2018/079154
Other languages
English (en)
French (fr)
Inventor
陈卫
王刚
陈潜
赵建新
张灏
Original Assignee
江南大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江南大学 filed Critical 江南大学
Priority to PCT/CN2018/079154 priority Critical patent/WO2019174003A1/zh
Publication of WO2019174003A1 publication Critical patent/WO2019174003A1/zh
Priority to US17/019,900 priority patent/US11213557B2/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A23L2/382—Other non-alcoholic beverages fermented
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the technical field of microorganisms, and particularly relates to Lactobacillus plantarum CCFM1019, fermented food thereof and application thereof in preparing medicine.
  • DEHP Di(2-ethylhexyl) phthalate
  • DEHP Di(2-ethylhexyl) phthalate Due to its low price, DEHP is widely used in the production of plastic products such as medical equipment and chemical products. It is the most widely used plasticizer in China. In these plastic products, DEHP is mainly combined with other molecules in the form of hydrogen bonds and van der Waals forces rather than covalent bonds, so it is easy to escape during use, thereby migrating to the environment and even the human body, to animals and plants and human bodies. Health produces harm.
  • DEHP metabolite mono(2-ethylhexyl) phthalate MEHP.
  • DEHP accumulated in the body and its metabolite MEHP can produce a variety of toxicity, including reproductive toxicity, liver toxicity, embryo toxicity, thyroid toxicity, neurotoxicity and the like.
  • DEHP is a peroxisome proliferator, it can break the intracellular redox balance and increase the level of free radicals such as ROS in cells.
  • DEHP and its metabolites can also cause lipid peroxidation by affecting the expression of antioxidant genes, leading to lipid peroxidation, resulting in lipid peroxides such as malondialdehyde, causing oxidative damage.
  • the present invention has been made in view of the above technical deficiencies.
  • the present invention overcomes the deficiencies in the prior art and provides a Lactobacillus plantarum (Lactobacillus plantarum) deposited on February 11, 2018 in the Guangdong Provincial Collection of Microorganisms and Cultures.
  • the deposit address is the Guangdong Institute of Microbiology, 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, with the preservation number GDMCC No. 60333.
  • the present invention overcomes the deficiencies in the prior art and provides a fermented food.
  • the present invention provides the following technical solution: the fermented food is produced by fermentation production using CCFM1019, and the fermented food includes solid food, liquid food, and semi-solid food.
  • the fermented food product comprises a dairy product, a soy product, a fruit and vegetable product, the dairy product comprising milk, sour cream, cheese; the fruit and vegetable product comprises cucumber, carrot , beets, celery, cabbage products.
  • the present invention overcomes the deficiencies in the prior art and provides the use of Lactobacillus plantarum CCFM1019 for the preparation of in vivo colonization of probiotics.
  • the present invention overcomes the deficiencies in the prior art and provides the use of Lactobacillus plantarum CCFM1019 in the preparation of a medicament for promoting the excretion of a plasticizer and a metabolite thereof in vivo.
  • Lactobacillus plantarum CCFM1019 of the present invention for the preparation of a medicament for promoting excretion of a plasticizer and a metabolite thereof in the body, wherein: the Lactobacillus plantarum CCFM1019 is resistant to gastric acid, bile salts, and promotion
  • the plasticizer and its metabolites are excreted from the body, reduce the content of plasticizers and their metabolites in serum, and significantly reduce the damage of the plasticizer and its metabolites to testicular tissue and liver tissue.
  • Lactobacillus plantarum CCFM1019 of the present invention for the preparation of a medicament for promoting excretion of a plasticizer and a metabolite thereof in a body, wherein: the plasticizer comprises bis(2-ethyl phthalate) Hexyl) ester and mono(2-ethylhexyl) phthalate.
  • the present invention overcomes the deficiencies in the prior art and provides the use of the fermented food according to claim 2 or 3 in the preparation of a functional food for promoting the discharge of a plasticizer and a metabolite thereof in the body.
  • a preferred embodiment of the fermented food of the present invention for use in the preparation of a functional food for promoting the excretion of a plasticizer and a metabolite thereof in the body, wherein the fermented food is resistant to gastric acid, bile salts, and plastication
  • the agent and its metabolites are excreted from the body, reduce the content of plasticizers and their metabolites in serum, and significantly reduce the damage of the plasticizer and its metabolites to testicular tissue and liver tissue.
  • the Lactobacillus plantarum CCFM1019 of the invention has good gastric acid and bile salt resistance, can promote the excretion of the plasticizer DEHP and its metabolite MEHP from the body, reduce its content in serum, and significantly reduce its Damage to testicular tissue and liver tissue.
  • Lactobacillus plantarum CCFM1019 of the present invention can be used as an effective means for preventing and alleviating body damage caused by DEHP and MEHP, and has no toxic side effects of drugs.
  • Lactobacillus plantarum CCFM1019 can be used to prepare pharmaceutical compositions and fermented foods for alleviating and preventing the toxicity of DEHP and its metabolites, and has a very broad application prospect.
  • Figure 1 is a schematic diagram showing the comparison of the adsorption capacity of the present strain and the control strains Lactobacillus rhamnosus GG (LGG), Escherichia coli and Enterococcus faecalis in vitro on DEHP and MEHP;
  • Figure 2 is a schematic diagram showing the effect of the strain of the present patent on the contents of DEHP and MEHP in serum and feces;
  • Figure 3 is a schematic diagram showing the improvement of testosterone levels in serum of DEHP exposed model rats by the patent strain
  • Figure 4 is a schematic diagram showing the effect of the strain of the present patent on the content of malondialdehyde (MDA) in the testis of a DEHP exposed model rat;
  • MDA malondialdehyde
  • Figure 5 is a schematic diagram showing the improvement of the tissue damage of the testis in the DEHP exposed model rats by the patent strain
  • Figure 6 is a graph showing the effect of the strain of the present patent on the contents of ALP, AST and ALT in serum of DEHP exposed model rats.
  • an embodiment or “an embodiment” as used herein refers to a particular feature, structure, or characteristic that can be included in at least one implementation of the invention.
  • the Lactobacillus plantarum of the present invention was deposited at the Guangdong Provincial Collection of Microorganisms and Cultures on February 11, 2018, and the deposit address is the 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, Guangdong province Institute of Microbiology The deposit number is GDMCC No.60333.
  • the Lactobacillus plantarum CCFM1019 has the following biological properties:
  • Characteristics of the bacteria It is positive for Gram stain, has acid resistance, grows well under the environment of pH 3.0-7.2, and does not form spores.
  • the cells are about (0.9-1.2) ⁇ m ⁇ (3.0-8.0) ⁇ m, bacillus brevis, single, paired or short-chain, usually lacking flagella but capable of movement;
  • Colony characteristics obvious colonies formed on MRS medium, diameter between 0.3-3.0mm, round, convex or lenticular, fine, white, smooth to mucus-like soft surface, no hyphae body;
  • the bacterium is a facultative anaerobic bacterium with an optimum growth temperature of 36-38 ° C, good growth at 32-38 ° C, and growth at 15 ° C.
  • the optimum initial pH is 6-7. Good growth in culture medium containing glucose;
  • the extraction method of this strain is:
  • the lactic acid bacteria obtained by the step (2) are cultured overnight, and 1 mL of the culture suspension is taken in a 1.5 mL centrifuge tube, centrifuged at 10000 ⁇ g for 2 min, and the supernatant is discarded;
  • Example 1 Lactobacillus plantarum CCFM1019 has good tolerance to simulated gastrointestinal fluid
  • the cryopreserved Lactobacillus plantarum CCFM1019 was streaked into MRS solid medium, and cultured at a temperature of 37 ° C for 24 h under aerobic conditions, and then subcultured for 2 to 3 times with MRS medium, and then the culture medium of Lactobacillus plantarum CCFM1019 was taken.
  • the survival rate is the ratio of the number of viable cells in the culture solution to the number of viable cells at the 0th hour, expressed in %.
  • the survival rate is a ratio of the number of viable cells at the
  • Lactobacillus plantarum CCFM1019 has good adsorption capacity for DEHP and MEHP in an aqueous solution containing plasticizer DEHP or MEHP in vitro.
  • the MRS liquid medium was added to the 1% (v/v) inoculum and cultured at 37 ° C for 20 h (E. coli was incubated with LB medium at 37 ° C; E .faecalis was cultured in MRS liquid medium at 37 ° C, then centrifuged at 8000 ⁇ g for 20 min, the supernatant was decanted, and resuspended in ultrapure water, and then centrifuged at 8000 ⁇ g for 20 min, and the supernatant was discarded. Living cells, that is, wet cells.
  • the wet bacteria were suspended in 50 mg/L DEHP or 10 mg/L MEHP aqueous solution, and the final bacterial concentration was 1 g wet bacteria/L.
  • the blank control was wet weight suspended in ultrapure water without DEHP and MEHP. . Each group has a volume of 1 mL.
  • the mixture was incubated at 37 ° C for 4 h with shaking, then centrifuged at 3500 ⁇ g for 10 min. The supernatant was collected and passed through a 0.22 ⁇ m filter.
  • the content of DEHP or MEHP in the filtrate was determined by UPLC-MS. value.
  • DEHP and MEHP adsorption measurement The content of DEHP or MEHP remaining in the filtrate was determined by UPLC-MS of Waters EYNAPT MS system, C18 column (2.1 ⁇ 100mm, 1.7 ⁇ m, Waters Co.), column temperature 35°C, injection volume It is 1 ⁇ L.
  • the A and B eluents were 100% methanol and 0.1% (v/v) aqueous formic acid, respectively, and the gradient was eluted at a flow rate of 0.3 mL/min. The gradient elution conditions are shown in Table 3.
  • Mass spectrometry conditions ionization source was ESI source; MRM detection (DEHP: MS+; MEHP: MS-); Capillary (capillary): 3.0 KV; Conc (vertebral body): 40.00 V; Source Temperature (radiation source temperature): 120 ° C; Desolvation temperature: 400 ° C; Conc Gas Flow: 50 L / h; Desolvation Gas Flow: 700 L / h. The gas flow rate was 0.1 mL/min; the mass-to-charge ratio scanning range was 100-2000; the scanning time was 1 s, and the interval was 0.061 s.
  • Adsorption rate (%) [(content of plasticizer in aqueous solution before adsorption - content of plasticizer in ultrapure water) - (content of plasticizer in supernatant after adsorption - supernatant plasticization in blank control) The content of the agent)] / (the content of the plasticizer in the aqueous solution before adsorption - the content of the plasticizer in the ultrapure water) ⁇ 100.
  • Example 3 Lactobacillus plantarum CCFM1019 has no acute side effects on SD rats
  • Lactobacillus plantarum CCFM1019 was resuspended in a 2% (w/v) sucrose solution with a cell density of 1.0 x 10 9 CFU/mL.
  • Ten healthy male Sprague-Dawley rats weighing about 100 g were administered with 2 mL of the suspension once a day for one week, and the death and body weight were recorded.
  • Example 4 Effect of Lactobacillus plantarum CCFM1019 on DEHP and MEHP in serum and feces of DEHP-exposed rats
  • the drinking water of the blank control group was changed to an aqueous solution containing 0.05% (m/V) sucrose fatty acid ester; DEHP was dissolved in 0.05% (m/V) aqueous solution of sucrose fatty acid ester, and the others were pressed except for the blank group.
  • the dose of 3000mg/kg body weight per day was used for drinking water, and probiotics and control 2% (w/v) sucrose solution were continued during the administration.
  • Four weeks after continuous exposure feces were collected and the animals were euthanized, testes and serum were collected, and DEHP and MEHP contents in serum and feces were measured. The results of the measurements are shown in Fig. 2.
  • Example 5 Lactobacillus plantarum CCFM1019 alleviates reproductive toxicity in DEHP-exposed rats
  • Example 4 The serum obtained in Example 4 was taken, and the testosterone content in the serum was measured according to the method shown in the ELISA kit. The result is shown in Figure 3.
  • Fig. 3 * indicates *P ⁇ 0.05, ** P ⁇ 0.01 compared with the control group.
  • testicular tissue obtained in Example 4 was weighed and added to physiological saline at a ratio of 1:9 (m/m), and disrupted in a tissue homogenizer to obtain 10% testicular tissue homogenate, and malondialdehyde in the homogenate was measured ( Malonaldehyde, MDA) level.
  • MDA Malonaldehyde
  • Example 6 Improvement of liver injury index in serum of DEHP-exposed rats by Lactobacillus plantarum CCFM1019
  • the serum of Example 4 was used to determine blood biochemical indicators in rats including alanine aminotransferase ALT, aspartate aminotransferase AST and alkaline phosphatase ALP. The results are shown in Fig. 6. In Fig. 6, * indicates significantness compared with the control group; *P ⁇ 0.05.
  • the DEHP exposure model group was compared with the serological index of the Lactobacillus plantarum CCFM1019 intervention group. As can be seen from Fig. 6, the Lactobacillus plantarum CCFM1019 of the present invention can effectively alleviate the abnormalities of AST, ALT and ALP indicators caused by DEHP intake.
  • the contents of AST in the blank control group, DEHP exposure model group and Lactobacillus plantarum CCFM1019 intervention group were 58.35 U/L, 124.58 U/L, 71.45 U/L, respectively; ALP in blank control group, DEHP exposure model group and Lactobacillus plantarum
  • the contents of the CCFM1019 intervention group were 174.25 U/L, 252.60 U/L, and 205.25 U/L, respectively.
  • the contents of ALT in the blank control group, DEHP exposure model group and Lactobacillus plantarum CCFM1019 intervention group were 20.00 U/L, 36.74 U, respectively. /L, 28.63U/L.
  • Example 7 Using the Lactobacillus plantarum CCFM1019 of the present invention to produce a fruit and vegetable beverage containing the same
  • the fresh vegetables are washed and then juiced, and then sterilized by high temperature, and then sterilized at a temperature of 140 ° C for 2 seconds, then immediately cooled to 37 ° C, and then connected to the plant Lactobacillus plantarum CCFM1019 fungicide,
  • the concentration was adjusted to 10 6 CFU/mL or more, and stored at a temperature of 4 ° C, whereby a fruit and vegetable beverage containing the live bacteria of the Lactobacillus plantarum CCFM1019 of the present invention was obtained.
  • Lactobacillus plantarum CCFM1019 which includes solid foods, liquid foods, and semi-solid foods.
  • the fermented food product comprises a dairy product, a soy product, a fruit and vegetable product, the dairy product comprising milk, sour cream, cheese; the fruit and vegetable product comprises cucumber, carrot, beet, celery, cabbage product.
  • the Lactobacillus plantarum CCFM1019 is resistant to gastric acid, bile salts, promotes the excretion of plasticizers and their metabolites from the body, reduces the content of plasticizers and their metabolites in serum, and significantly reduces plasticizers and their metabolites. Damage to testicular tissue and liver tissue.
  • the Lactobacillus plantarum CCFM1019 of the invention has good resistance to gastric acid and bile salts, can promote the excretion of the plasticizer DEHP and its metabolite MEHP from the body, reduce its content in serum, and significantly reduce its testicular tissue and liver tissue. The damage effect.
  • Lactobacillus plantarum CCFM1019 of the present invention can be used as an effective means for preventing and alleviating body damage caused by DEHP and MEHP, and has no toxic side effects of drugs.
  • Lactobacillus plantarum CCFM1019 can be used to prepare pharmaceutical compositions and fermented foods for alleviating and preventing the toxicity of DEHP and its metabolites, and has a very broad application prospect.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

植物乳杆菌CCFM1019、其发酵食品及其在制备药物中的应用。该菌在促进DEHP及MEHP排出的功效方面不仅优于肠道常驻菌群大肠杆菌和粪肠球菌，且优于商业菌株鼠李糖乳杆菌LGG，可用于制备缓解、预防DEHP及其代谢产物毒性的药物组合物与发酵食品。

Description

植物乳杆菌CCFM1019、其发酵食品及其在制备药物中的应用 技术领域
本发明属于微生物技术领域，具体涉及植物乳杆菌CCFM1019、其发酵食品及其在制备药物中的应用。
背景技术
邻苯二甲酸二(2-乙基己基)酯(以下简称DEHP)作为一种塑化剂，添加在塑料中可增加其柔韧性和可塑性。因价格低廉，DEHP被广泛地应用于生产医药器材、化工产品等塑料制品，是我国目前使用最广泛的塑化剂。在这些塑料产品中，DEHP主要以氢键和范德华力而非共价键的形式与其他分子结合，因此在使用的过程中极易逸出，从而迁移到环境甚至人体中，对动植物和人体健康产生危害。
研究表明，DEHP在人体内吸收和分布期持续约4～8h，大部分可在24h内被人体完全代谢。尿液是DEHP主要的排出途径。DEHP进入体内24h后，小于10％的DEHP原液直接经尿液排出，约67％的DEHP转化为五种二次代谢产物经尿液排出。由于DEHP具有脂溶性，少数DEHP则滞留于脂肪或乳汁中。储存于脂肪组织中的DEHP长时间不能被完全代谢，半衰期长达156h。
DEHP对机体的毒性作用主要由其代谢产物邻苯二甲酸单(2-乙基己基)酯MEHP发挥。积累在体内的DEHP及其代谢产物MEHP可产生多种毒性，包括生殖毒性、肝脏毒性、胚胎毒性、甲状腺毒性、神经毒性等。由于DEHP是一种过氧化物酶体增殖剂，可以打破细胞内的氧化还原平衡，使细胞内ROS等自由基水平升高。此外，DEHP及其代谢产物还可通过影响抗氧化基因的表达，导致ROS积累从而引发脂质过氧化，产生丙二醛等脂质过氧化物，引起氧化损伤。目前主要通过服用一些如维生素C，维生素E，葡萄籽精华、黄酮类等具有抗氧化作用的生物活性物质来预防和缓解DEHP对人体的损害。然而，要通过补充活性物质来缓解DEHP的毒性作用需要较大的剂量，而且过量摄取活性物质也会引起机体产生副作用，例如过量黄酮类物质的摄入则会引起人体内分泌紊乱。且以上的方法并不能降低机体内摄入及残留的塑化剂。因此，寻找一种新型、安全的预防和治疗方法显得尤为必要。
在目前已经公开的文献中，未见通过益生菌缓解塑化剂毒害的专利。据已有的文献报道，益生菌在体外对DEHP最高吸附率仅为9.62％，吸附效果并不理想。因此开发出一种对塑化剂具备较强吸附能力的益生菌，并且通过动物实 验证明其能在体内具有良好的缓解塑化剂毒性损伤的作用显得尤为重要。
发明内容
本部分的目的在于概述本发明的实施例的一些方面以及简要介绍一些较佳实施例。在本部分以及本申请的说明书摘要和发明名称中可能会做些简化或省略以避免使本部分、说明书摘要和发明名称的目的模糊，而这种简化或省略不能用于限制本发明的范围。
鉴于上述的技术缺陷，提出了本发明。
因此，作为本发明其中一个方面，本发明克服现有技术中存在的不足，提供一种植物乳杆菌CCFM1019，(Lactobacillus plantarum)，于2018年2月11日保藏于广东省微生物菌种保藏中心，保藏地址为广州市先烈中路100号大院59号楼5楼广东省微生物研究所，保藏编号为GDMCC No.60333。
作为本发明另一个方面，本发明克服现有技术中存在的不足，提供一种发酵食品。
为解决上述技术问题，本发明提供了如下技术方案：所述发酵食品为使用CCFM1019发酵生产制得，所述发酵食品包括固态食品、液态食品、半固态食品。
作为本发明所述的发酵食品的一种优选方案，其中：所述发酵食品包括乳制品、豆制品、果蔬制品，所述乳制品包括牛奶、酸奶油、干酪；所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
作为本发明另一个方面，本发明克服现有技术中存在的不足，提供植物乳杆菌CCFM1019在制备体内定植益生菌中的应用。
作为本发明另一个方面，本发明克服现有技术中存在的不足，提供植物乳杆菌CCFM1019在制备促进体内塑化剂及其代谢产物的排出的药物中的应用。
作为本发明所述植物乳杆菌CCFM1019在制备促进体内塑化剂及其代谢产物的排出的药物中的应用的一种优选方案，其中：所述植物乳杆菌CCFM1019能够耐胃酸、耐胆盐、促进塑化剂及其代谢产物从体内排出、减少塑化剂及其代谢产物在血清中的含量、显著地减轻塑化剂及其代谢产物对睾丸组织和肝脏组织的损害。
作为本发明所述植物乳杆菌CCFM1019在制备促进体内塑化剂及其代谢产物的排出的药物中的应用的一种优选方案，其中：所述塑化剂包括邻苯二甲 酸二(2-乙基己基)酯和邻苯二甲酸单(2-乙基己基)酯。
作为本发明另一个方面，本发明克服现有技术中存在的不足，提供权利要求2或3所述的发酵食品在制备促进体内塑化剂及其代谢产物的排出的功能性食品中的应用。
作为本发明所述发酵食品在制备促进体内塑化剂及其代谢产物的排出的功能性食品中的应用的一种优选方案，其中：所述发酵食品能够耐胃酸、耐胆盐、促进塑化剂及其代谢产物从体内排出、减少塑化剂及其代谢产物在血清中的含量、显著地减轻塑化剂及其代谢产物对睾丸组织和肝脏组织的损害。
本发明的有益效果：本发明的植物乳杆菌CCFM1019具有良好的耐胃酸耐胆盐特性，能够促进塑化剂DEHP及其代谢产物MEHP从体内排出，减少其在血清中的含量，显著地减轻其对睾丸组织和肝脏组织的损害作用。
该菌在体外吸附DEHP及MEHP效果方面(分别为52.22％和70.54％)不仅显著优于肠道常驻菌群大肠杆菌(DEHP:5.86％，MEHP:0.28％)和粪肠球菌(DEHP:1.75％，MEHP：0.17％)，且优于商业菌株鼠李糖乳杆菌LGG(DEHP:13.75％，MEHP:15.60％)。在大鼠体内，可显著降低血清中DEHP和MEHP含量(对比空白对照组分别降低54.3％和55.7％)，同时提高DEHP及MEHP在粪便中的含量(对比空白对照组分别提高了34.18％和93.88％)。因此，本发明的植物乳杆菌CCFM1019可以作为预防和缓解因DEHP和MEHP造成的机体损伤的有效手段，且不具有药物的毒副作用。植物乳杆菌CCFM1019可用于制备缓解、预防DEHP及其代谢产物毒性的药物组合物与发酵食品，具有非常广泛的应用前景。
附图说明
为了更清楚地说明本发明实施例的技术方案，下面将对实施例描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图仅仅是本发明的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动性的前提下，还可以根据这些附图获得其它的附图。其中：
图1是本专利菌株及对照菌株Lactobacillus rhamnosus GG(LGG)、Escherichia coli及Enterococcus faecalis在体外对DEHP和MEHP的吸附能力的比较示意图；
图2是本专利菌株对血清和粪便中DEHP及MEHP含量的影响示意图；
图3是本专利菌株对DEHP暴露模型大鼠血清中睾酮水平的改善情况示意图；
图4是本专利菌株对DEHP暴露模型大鼠睾丸中丙二醛(MDA)含量的影响示意图；
图5是本专利菌株对DEHP暴露模型大鼠睾丸部位组织损伤的改善情况示意图；
图6是本专利菌株对DEHP暴露模型大鼠血清中ALP，AST和ALT含量的影响示意图。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂，下面结合具体实施例对本发明的具体实施方式做详细的说明。
在下面的描述中阐述了很多具体细节以便于充分理解本发明，但是本发明还可以采用其他不同于在此描述的其它方式来实施，本领域技术人员可以在不违背本发明内涵的情况下做类似推广，因此本发明不受下面公开的具体实施例的限制。
其次，此处所称的“一个实施例”或“实施例”是指可包含于本发明至少一个实现方式中的特定特征、结构或特性。在本说明书中不同地方出现的“在一个实施例中”并非均指同一个实施例，也不是单独的或选择性的与其他实施例互相排斥的实施例。
本发明的植物乳杆菌CCFM1019(Lactobacillus plantarum)，于2018年2月11日保藏于广东省微生物菌种保藏中心，保藏地址为广州市先烈中路100号大院59号楼5楼广东省微生物研究所，保藏编号为GDMCC No.60333。
所述植物乳杆菌CCFM1019具有下述生物学特性：
(1)菌体特征：呈革兰氏染色阳性，具有耐酸性，在pH 3.0-7.2环境条件下生长良好，不形成孢子。菌体约(0.9-1.2)μm×(3.0-8.0)μm，圆端直杆菌，单个、成对或短链状，通常缺乏鞭毛但能运动；
(2)菌落特征：在MRS培养基上形成明显的菌落，直径在0.3-3.0mm之间，圆形，凸面或透镜状，细密、色白，有平滑至粘液状的柔软表面，不形成菌丝体；
(3)生长特性：该菌为兼性厌氧菌，最适生长温度为36-38℃，32-38℃生长良好，15℃亦能生长。最适初始pH为6-7。在含有葡萄糖的培养液中生长良 好；
(4)对人工模拟胃肠液具有较好的耐受能力；
(5)能够缓解DEHP及代谢产物MEHP对睾丸的损伤；
(6)能显著增加粪便中DEHP和MEHP水平；
(7)能显著降低血清中DEHP和MEHP水平，降低DEHP和MEHP在机体内的积累；
(8)能显著改善血清中谷丙转氨酶ALT(glutamic-pyruvic transaminase)，谷草转氨酶AST(glutamic oxalacetic transaminase)和碱性磷酸酶ALP(alkaline phosphatase)水平。
本菌株的提取方法为：
(一)乳酸菌的分离筛选
(l)收集产自不同地区的泡菜样本，将样品在含有山梨醇MRS培养基中富集12h；
(2)将富集样品进行梯度稀释后涂布于添加了0.02％嗅甲酚紫的MRS固体平板上，培养24-48h；
(3)选取变色圈明显，并且符合乳酸菌基本形态的单菌落进行平板划线纯化，筛选分离出乳酸菌；
(4)将上述单菌落培养于液体MRS培养液中培养24h后进行革兰氏染色，选取革兰氏阳性菌进行后续试验。
(二)植物乳杆菌的初步鉴定：溶钙圈测定法
(l)将步骤(一)所筛选得到的乳酸菌在液体山梨醇MRS培养液中培养24h，然后取lmL培养物8000×g离心2min；
(2)用0.05M KH 2PO 4溶液洗涤两次；
(3)将所得菌泥重悬，划线在山梨醇MRS-0.75％CaCO 3的固体培养基上，培养24h；
(4)选取溶钙圈明显，且呈凸面圆形、细密色白、无菌丝体的菌落，革兰氏染色后显微镜观察菌体为杆状即初步判定为乳杆菌。
(三)植物乳杆菌的分子生物学鉴定
(l)单菌基因组抽提
A.将步骤(二)所筛选得到的乳酸菌培养过夜，取培养过夜的菌悬液lmL于1.5mL离心管，10000×g离心2min，弃上清得菌体；
B.用lmL无菌水吹洗菌体后，10000×g离心2min，弃上清得菌体；
C.加入200μL SDS裂解液，80℃水浴30min；
D.加入酚-氯仿溶液200μL于菌体裂解液中，其中酚-氯仿溶液的组成成分及体积比为Tris饱和酚:氯仿:异戊醇＝25:24:1，颠倒混匀后，12000×g离心5-10min，取上清200μL；
E.加入400μL冰乙醇或冰异丙醇于200μL上清中，﹣20℃静置1h，12000×g离心5-10min，弃上清；
F.加入500μL 70％(体积百分数)冰乙醇重悬沉淀，12000×g离心1-3min，弃上清；
G.60℃烘箱烘干，或者自然晾干；
H.50μLddH 2O重溶沉淀以备PCR；
(2)16S rDNA PCR
A.细菌16S rDNA 50μLPCR反应体系：
10×Taq buffer，5μL；dNTP，5μL；27F，0.5μL；1492R，0.5μL；Taq酶，0.5μL；模板，0.5μL；ddH 2O，38μL。
B.PCR条件：
95℃5min；95℃10s；55℃30s；72℃30s；step2-4 30×；72℃5min；12℃2min；
(3)制备1％琼脂糖凝胶，之后将PCR产物与10×loading buffer混合，上样量5μL，120V跑30min，然后进行凝胶成像；
(4)将16S rDNA的PCR产物进行测序分析，将得到的序列结果使用BLAST在GeneBank中进行搜索和相似性比对，选取测序结果鉴定为属于乳酸乳球菌的一种新的乳酸菌目菌株，-80℃保藏备用。
实施例1：植物乳杆菌CCFM1019在对模拟胃肠液具有良好的耐受性
将冷冻保存的植物乳杆菌CCFM1019划线接种于MRS固体培养基中，在温度37℃有氧静置培养24h，再经MRS培养液传代培养2～3次后，取植物乳杆菌CCFM1019培养液，8000×g离心5min收集菌体，重悬于(1:1)pH 2.5的人工模拟胃液(含1％胃蛋白酶、pH＝2.5的MRS培养基)混合，然后在37℃下有氧培养，分别在开始(0h)、1h、2h和3h时取样，用MRS琼脂培养基浇注培养进行平板菌落计数，测定活菌数并计算其存活率。存活率是在该培养液中的活菌数与在第0h时活菌数之比，以％表示。
取植物乳杆菌CCFM1019的培养液，8000×g离心5min收集菌体，重悬于(1:1)人工模拟肠液(含0.3％牛胆盐、1％胰蛋白酶、pH＝8.0的MRS培养基)中，在37℃下有氧培养，分别在0h、1h、2h、3h和4h时取样，用MRS琼脂培养基浇注培养进行平板菌落计数，测定活菌数并计算其存活率。存活率是在该培养液中取样时的活菌数与在第0h时活菌数之比，以％表示。实验结果如表1、表2所示，可以看到植物乳杆菌CCFM1019对人工胃、肠液具有良好的耐受性。
表1 植物乳杆菌CCFM1019在人工模拟胃液中的耐受性
Figure PCTCN2018079154-appb-000001
表2 植物乳杆菌CCFM1019在人工模拟肠液中的耐受性
Figure PCTCN2018079154-appb-000002
实施例2：植物乳杆菌CCFM1019在体外含塑化剂DEHP或MEHP水溶液中对DEHP和MEHP具有良好的吸附能力
菌体吸附：将实验菌进行纯化和活化培养后，按照1％(v/v)接种量接入MRS液体培养基，于37℃培养20h(E.coli使用LB培养基于37℃震荡培养；E.faecalis使用MRS液体培养基于37℃培养)，然后在8000×g条件下离心20min，倒掉上清，并用超纯水重悬后继续在8000×g条件下离心20min，倒掉上清即得活菌体细胞，即湿菌体。将湿菌体重悬于50mg/L DEHP或者10mg/L MEHP水溶液中，并使最终菌体浓度达到1g湿菌体/L，空白对照为湿菌体重悬于不含 DEHP和MEHP的超纯水中。每组体积为1mL。将混合液于37℃振荡温育4h，然后于3500×g离心10min，收集上清液并过0.22μm滤膜后，用UPLC-MS测定滤液中DEHP或MEHP的含量，3次平行实验取平均值。
DEHP和MEHP吸附量测定：采用Waters EYNAPT MS系统的UPLC-MS测定滤液中剩余的DEHP或MEHP的含量，C18柱(2.1×100mm，1.7μm，Waters Co.)，柱温35℃，进样量为1μL。A，B洗脱液分别为100％甲醇和0.1％(v/v)甲酸水溶液，梯度洗脱，流速为0.3mL/min。梯度洗脱条件如表3所示。
表3 梯度洗脱条件
t/min 0-0.5 0.5-7.0 7.0-7.5 7.5-10.0
洗脱液A比例 60％ 60-100％ 100-60％ 60％
质谱条件：电离源为ESI源；MRM检测(DEHP:MS+；MEHP:MS-)；Capillary(毛细管):3.0KV；Conc(椎体):40.00V；Source Temperature(放射源温度)：120℃；Desolvation(去溶剂化)温度：400℃；Conc Gas Flow:50L/h；Desolvation Gas Flow:700L/h。气体流速为0.1mL/min；质荷比扫描范围：100-2000；扫面时间1s，间隔0.061s。结果用MassLynxV4.1(Waters公司)分析；在这项研究中，DEHP和MEHP的最低检测限分别为0.05ppm和0.1ppm。根据吸附前后的DEHP或者MEHP浓度差异计算乳酸菌的吸附率，吸附率按一下公式计算：
吸附率(％)＝[(吸附前水溶液中塑化剂的含量-超纯水中塑化剂的含量)-(吸附后上清液中塑化剂的含量-空白对照中上清液塑化剂的含量)]/(吸附前水溶液中塑化剂的含量-超纯水中塑化剂的含量)×100。
这些测定结果列于附图1中，从图1中可明显看出，与商业菌LGG(DEHP:13.75％，MEHP:15.60％)和肠道常驻菌E.coli(DEHP:5.86％，MEHP:0.28％)及E.faecalis(DEHP:1.75，MEHP:0.17％)相比，本发明植物乳杆菌CCFM1019对DEHP和MEHP的吸附率(DEHP:52.22％，MEHP:70.54％)均显著高于对照菌，且远远高于已有报导的DEHP 9.62％的吸附率。因此，植物乳杆菌CCFM1019对DEHP和MEHP具有良好的吸附能力。
实施例3：植物乳杆菌CCFM1019对SD大鼠无急性毒副作用
将植物乳杆菌CCFM1019重悬于2％(w/v)蔗糖溶液中，菌体密度为1.0× 10 9CFU/mL。取体重100g左右的健康雄性SD大鼠10只，每日给予该浓度悬液灌胃2mL，观察一周，记录死亡和体重情况。
这些试验结果列于表4中。结果表明，喂食浓度1.0×10 9CFU/mL的植物乳杆菌CCFM1019未对大鼠造成明显影响，体重无显著变化，无死亡现象产生。大鼠外观无明显病理症状。
表4 大鼠体重的变化及死亡情况
Figure PCTCN2018079154-appb-000003
注：-：大鼠无死亡
实施例4：植物乳杆菌CCFM1019对DEHP暴露大鼠血清和粪便中DEHP及MEHP含量影响
取体重100g左右的健康雄性SD大鼠18只，随机分为3组：空白对照组(control)、DEHP暴露模型组(DEHP)、植物乳杆菌CCFM1019干预组(DEHP+CCFM1018)，每组含大鼠6只。试验第1-7天，空白对照组和DEHP暴露模型组每天灌胃2mL 2％(w/v)蔗糖溶液，植物乳杆菌CCFM1019干预组大鼠灌喂按本说明书实施例3制备的浓度为1.0×10 9CFU/mL的植物乳杆菌CCFM1019悬液2mL。第8天，将空白对照组的饮水换为含0.05％(m/V)蔗糖脂肪酸酯水溶液；将DEHP溶解于0.05％(m/V)蔗糖脂肪酸酯水溶液中，其他除空白组外按3000mg/kg体重·天的染毒剂量进行饮水染毒，染毒期间继续进行益生菌及对照2％(w/v)蔗糖溶液灌胃。连续染毒四周后，收集粪便并将动物安乐处死，收集睾丸和血清，测定血清和粪便中DEHP和MEHP含量，该测定结果列于附图2中。*表示与对照组中的DEHP含量相比具有显著性；*P＜0.05,**P＜0.01，***P<0.005，****P<0.001；#P<0.05，##P<0.01，###P<0.005，####P<0.001。
实验结果表明，植物乳杆菌CCFM1019干预后，可显著降低血清中DEHP和MEHP含量(对比空白对照组分别降低54.3％和55.7％)，同时提高DEHP及MEHP在粪便中的含量(对比空白对照组分别提高了34.18％和93.88％)，由此可见植物乳杆菌CCFM1019可有效促进DEHP及代谢产物MEHP从机体的排出。
实施例5：植物乳杆菌CCFM1019对DEHP暴露大鼠生殖毒性的缓解作用
取实施例4得到的血清，根据ELISA试剂盒所示方法测定血清中睾酮含量。结果如图3所示。图3中，*表示与对照组中相比，*P＜0.05,**P＜0.01。
称取实施例4中得到的睾丸组织，按1：9(m/m)比例加入生理盐水，于组织匀浆仪中破碎，得10％的睾丸组织匀浆液，测定匀浆液中丙二醛(malonaldehyde，MDA)水平。测定结果列于附图4中。图4中*表示与对照组相比具有显著性，#表示与DEHP模型组相比具有显著性；*P＜0.05，#P＜0.05。
取睾丸组织进行石蜡切片操作并进行常规H&E染色。染色结果如图5所示。
通过对DEHP暴露模型组及植物乳杆菌CCFM1019干预组血清中睾酮含量、睾丸中MDA水平及睾丸病变指标的比较，发现本发明植物乳杆菌CCFM1019能够缓解由DEHP摄入导致的大鼠血清中睾酮含量的异常(DEHP暴露模型组：19.65mmol/L，CCFM1019干预组：35.99mmol/L)，降低睾丸组织中MDA的含量(DEHP暴露模型组：50.28nmol/mg，CCFM1019干预组：29.32nmol/mg)，缓解睾丸组织损伤，对DEHP摄入造成的生殖损伤起到了显著的缓解作用。
实施例6：植物乳杆菌CCFM1019对DEHP暴露大鼠血清中肝脏损伤指标的改善
取实施例4中血清用于测定大鼠的血液生化指标包括谷丙转氨酶ALT，谷草转氨酶AST和碱性磷酸酶ALP。结果如图6所示，图6中*表示与对照组中相比具有显著性；*P＜0.05。通过DEHP暴露模型组与植物乳杆菌CCFM1019干预组血清学指标进行比较，从图6可知，本发明植物乳杆菌CCFM1019能够有效缓解因DEHP摄入导致的AST、ALT和ALP指标异常。AST在空白对照组，DEHP暴露模型组和植物乳杆菌CCFM1019干预组的含量分别为58.35U/L，124.58U/L，71.45U/L；ALP在空白对照组，DEHP暴露模型组和植物乳杆菌CCFM1019干预组的含量分别为174.25U/L，252.60U/L，205.25U/L；ALT在空白对照组，DEHP暴露模型组和植物乳杆菌CCFM1019干预组的含量分别为20.00U/L，36.74U/L，28.63U/L。
实施例7：利用本发明植物乳杆菌CCFM1019制造含该菌的果蔬饮料
选用新鲜蔬菜洗净后榨汁，接着进行高温瞬间灭菌，在温度140℃下高温 热杀菌2秒后，立即降温至37℃，再接入本发明制备的植物乳杆菌CCFM1019菌剂发酵剂，使其浓度达到10 6CFU/mL以上，在温度4℃下冷藏保存，于是得到含有本发明植物乳杆菌CCFM1019活菌的果蔬饮料。
利用本发明能够使用植物乳杆菌CCFM1019发酵生产制备其他发酵食品，所述发酵食品包括固态食品、液态食品、半固态食品。所述发酵食品包括乳制品、豆制品、果蔬制品，所述乳制品包括牛奶、酸奶油、干酪；所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。所述植物乳杆菌CCFM1019能够耐胃酸、耐胆盐、促进塑化剂及其代谢产物从体内排出、减少塑化剂及其代谢产物在血清中的含量、显著地减轻塑化剂及其代谢产物对睾丸组织和肝脏组织的损害。
本发明的植物乳杆菌CCFM1019具有良好的耐胃酸耐胆盐特性，能够促进塑化剂DEHP及其代谢产物MEHP从体内排出，减少其在血清中的含量，显著地减轻其对睾丸组织和肝脏组织的损害作用。
该菌在体外吸附DEHP及MEHP效果方面(分别为52.22％和70.54％)不仅显著优于肠道常驻菌群大肠杆菌(DEHP:5.86％，MEHP:0.28％)和粪肠球菌(DEHP:1.75％，MEHP：0.17％)，且优于商业菌株鼠李糖乳杆菌LGG(DEHP:13.75％，MEHP:15.60％)。在大鼠体内，可显著降低血清中DEHP和MEHP含量(对比空白对照组分别降低54.3％和55.7％)，同时提高DEHP及MEHP在粪便中的含量(对比空白对照组分别提高了34.18％和93.88％)。因此，本发明的植物乳杆菌CCFM1019可以作为预防和缓解因DEHP和MEHP造成的机体损伤的有效手段，且不具有药物的毒副作用。植物乳杆菌CCFM1019可用于制备缓解、预防DEHP及其代谢产物毒性的药物组合物与发酵食品，具有非常广泛的应用前景。
应说明的是，以上实施例仅用以说明本发明的技术方案而非限制，尽管参照较佳实施例对本发明进行了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的精神和范围，其均应涵盖在本发明的权利要求范围当中。

Claims (9)

  1. 一种植物乳杆菌CCFM1019(Lactobacilus plantarum)，于2018年2月11日保藏于广东省微生物菌种保藏中心，保藏地址为广州市先烈中路100号大院59号楼5楼广东省微生物研究所，保藏编号为GDMCC No.60333。
  2. 一种发酵食品，其特征在于：所述发酵食品为使用CCFM1019发酵生产制得，所述发酵食品包括固态食品、液态食品、半固态食品。
  3. 如权利要求2所述的发酵食品，其特征在于：所述发酵食品包括乳制品、豆制品、果蔬制品，所述乳制品包括牛奶、酸奶油、干酪；所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
  4. 植物乳杆菌CCFM1019在制备促进体内塑化剂及其代谢产物的排出的药物中的应用。
  5. 如权利要求4所述的应用，其特征在于：所述植物乳杆菌CCFM1019能够耐胃酸、耐胆盐、促进塑化剂及其代谢产物从体内排出、减少塑化剂及其代谢产物在血清中的含量、显著地减轻塑化剂及其代谢产物对睾丸组织和肝脏组织的损害。
  6. 如权利要求4或5所述的应用，其特征在于：所述塑化剂包括邻苯二甲酸二(2-乙基己基)酯和邻苯二甲酸单(2-乙基己基)酯。
  7. 权利要求2或3所述的发酵食品在制备促进体内塑化剂及其代谢产物的排出的功能性食品中的应用。
  8. 如权利要求7所述的应用，其特征在于：所述发酵食品能够耐胃酸、耐胆盐、促进塑化剂及其代谢产物从体内排出、减少塑化剂及其代谢产物在血清中的含量、显著地减轻塑化剂及其代谢产物对睾丸组织和肝脏组织的损害。
  9. 如权利要求8所述的应用，其特征在于：所述减轻塑化剂及其代谢产物对睾丸组织和肝脏组织的损害，包括缓解因所述塑化剂的摄入导致的AST、ALT和ALP指标异常。
PCT/CN2018/079154 2018-03-15 2018-03-15 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用 WO2019174003A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/079154 WO2019174003A1 (zh) 2018-03-15 2018-03-15 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用
US17/019,900 US11213557B2 (en) 2018-03-15 2020-09-14 Lactobacillus plantarum CCFM1019, fermented foods thereof, and application thereof in preparation of medicine for promoting excretion of plasticizers and metabolites thereof from body

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/079154 WO2019174003A1 (zh) 2018-03-15 2018-03-15 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/019,900 Continuation US11213557B2 (en) 2018-03-15 2020-09-14 Lactobacillus plantarum CCFM1019, fermented foods thereof, and application thereof in preparation of medicine for promoting excretion of plasticizers and metabolites thereof from body

Publications (1)

Publication Number Publication Date
WO2019174003A1 true WO2019174003A1 (zh) 2019-09-19

Family

ID=67908496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/079154 WO2019174003A1 (zh) 2018-03-15 2018-03-15 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用

Country Status (2)

Country Link
US (1) US11213557B2 (zh)
WO (1) WO2019174003A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213557B2 (en) * 2018-03-15 2022-01-04 Jiangnan University Lactobacillus plantarum CCFM1019, fermented foods thereof, and application thereof in preparation of medicine for promoting excretion of plasticizers and metabolites thereof from body

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113308394B (zh) * 2021-04-26 2023-09-05 西北工业大学 鼠李糖乳杆菌微生态制剂及其制备方法和应用
CN113186139B (zh) * 2021-06-21 2022-06-07 西北民族大学 一株植物乳杆菌lr002及其应用
CN117821288A (zh) * 2022-04-27 2024-04-05 无限极（中国）有限公司 一种促进体内塑化剂及重金属排出的益生菌及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107523514A (zh) * 2017-07-17 2017-12-29 四川农业大学 一株有效吸附邻苯二甲酸单酯的产胞外多糖植物乳杆菌

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108384735B (zh) * 2018-03-15 2020-05-12 江南大学 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用
WO2019174003A1 (zh) * 2018-03-15 2019-09-19 江南大学 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107523514A (zh) * 2017-07-17 2017-12-29 四川农业大学 一株有效吸附邻苯二甲酸单酯的产胞外多糖植物乳杆菌

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213557B2 (en) * 2018-03-15 2022-01-04 Jiangnan University Lactobacillus plantarum CCFM1019, fermented foods thereof, and application thereof in preparation of medicine for promoting excretion of plasticizers and metabolites thereof from body

Also Published As

Publication number Publication date
US20200405790A1 (en) 2020-12-31
US11213557B2 (en) 2022-01-04

Similar Documents

Publication Publication Date Title
CN108384735B (zh) 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用
CN111235070B (zh) 一株母乳婴儿源植物乳杆菌bf_15及其应用
US11213557B2 (en) Lactobacillus plantarum CCFM1019, fermented foods thereof, and application thereof in preparation of medicine for promoting excretion of plasticizers and metabolites thereof from body
CN108076643B (zh) 用于治疗例如细菌性阴道病的鼠李糖乳杆菌细菌
US11492588B2 (en) Lactococcus lactis subsp. lactis CCFM1018 and application thereof in preparation of food and medicine for excreting plasticizer
WO2022057741A1 (zh) 动物双歧杆菌及其选育方法和应用
CN113337430B (zh) 一株副干酪乳杆菌nsl0201及其应用
CN110564638A (zh) 一株具有益生特性的罗伊氏乳杆菌及其用途
BR112012020975B1 (pt) bactéria pertencente ao gênero bifidobacterium, alimento ou bebida, usos de um fragmento de dna e de um conjunto de iniciadores e métodos para a detecção e quantificação da dita bactéria
CN116024130A (zh) 一株降血尿酸发酵乳杆菌a21215及其应用
CN110833565B (zh) 植物乳杆菌gkm3的活性物质、含其的组合物及其促进长寿的用途
KR20230154400A (ko) 락토바실러스 플란타럼 hom3201 균주 및 이의 생균 제제, 제조 방법 및 용도
CN113943681A (zh) 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌
CN111714572A (zh) 一种基于植物乳杆菌的益生菌片剂及其制备方法
CN116970539B (zh) 一种鼠联合乳杆菌、其组合物及用途
CN117004503B (zh) 一株唾液联合乳杆菌mb1及其在制备助睡眠和调理肠胃食品药品中的应用
CN116555075B (zh) 一株植物乳植杆菌jf1及其在制备抗衰老食品药品中的应用
CN116790431A (zh) 能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用
CN116445356A (zh) 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用
WO2019174002A1 (zh) 戊糖片球菌ccfm1012、其发酵食品及其在制备拮抗空肠弯曲杆菌感染药物中的应用
CN117821288A (zh) 一种促进体内塑化剂及重金属排出的益生菌及其应用
ES2740979T3 (es) Bacteria Lactobacillus rhamnosus para el tratamiento de, por ejemplo, la vaginosis bacteriana
CN117264850B (zh) 一种具有辅助治疗阴道炎和增强免疫力功能的戊糖片球菌sw006及其应用
CN117004513B (zh) 可促进运动恢复的鼠李糖乳杆菌及其应用
CN116445352A (zh) 一种副干酪乳杆菌（Lacticaseibacillus paracasei）HCLP01及其在制备具有抗氧化或抗衰老作用的产品中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18910124

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18910124

Country of ref document: EP

Kind code of ref document: A1